The lotion, intended to treat skin conditions like eczema and psoriasis, represents Teligent’s sixth approval from its internally developed portfolio of topical generic drug products, according to a news release.
The company plans to launch the lotion in the first quarter of 2017.
More articles on supply chain:
Addiction centers pay more than $700k to resolve allegations of improper prescribing
Court orders contracted pilots for Amazon, DHL to return to work after strike
DEA bans furanyl fentanyl
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.